Biofil Chemicals & Pharmaceuticals Limited
NSE: BIOFILCHEM · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Biofil Chemicals & Pharmaceuticals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Biofil Chemicals and Pharmaceuticals Ltd is an Indian company engaged in the manufacturing and trading of pharmaceutical and chemical products. The company operates through two primary divisions and provides job work facilities for pharmaceutical drug manufacturing.
Business Model
The company generates revenue through the direct sale of pharmaceutical and chemical products alongside providing contract manufacturing services for third-party drug production.
Growth Outlook
Growth is expected to be driven by the expansion of its pharmaceutical and chemical manufacturing capabilities and the utilisation of its job work facilities.
Key Risks
- Regulatory Compliance. The pharmaceutical sector is subject to stringent government regulations and quality standards that can impact operational continuity.
- Market Competition. Intense competition within the Indian pharmaceutical and chemical landscape may exert pressure on profit margins.
- Raw Material Price Volatility. Fluctuations in the cost of chemical inputs can significantly affect the production costs and overall profitability of the company.
Start your research today
Unlock AI insights, financials, peers and live data on Biofil Chemicals & Pharmaceuticals Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹28 Cr
TTM · standalone
NET PROFIT
₹3 Cr
TTM · standalone
EPS
₹1.71
TTM · standalone
RETURN ON EQUITY
14.3%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
17.4%
TTM · standalone
P/E
17.1x
Q4 FY26 · standalone
EV/EBITDA
14.8x
Q4 FY26 · standalone
EBITDA MARGIN
13.2%
TTM · standalone
NET PROFIT MARGIN
2.8%
Q4 FY26 · standalone
DEBT TO EQUITY
0.1x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Biofil Chemicals & Pharmaceuticals LimitedBIOFILCHEM | ₹53 Cr | 17.14 | 14.84 | -15.0% | 13.2% | 14.3% | 17.4% | -29.4% |
TranschemTRANSCHEM | ₹502 Cr | 75.62 | 52.99 | -100.0% | 177.7% | 8.3% | 10.6% | +600.8% |
Albert DavidALBERTDAVD | ₹501 Cr | 21.67 | 13.19 | 11.4% | 11.0% | 5.8% | 7.5% | +10.3% |
Haleos Labs LimitedHALEOSLABS | ₹457 Cr | 28.51 | 12.83 | -3.1% | 13.6% | 7.4% | 10.3% | — |
Medicamen BiotecMEDICAMEQ | ₹434 Cr | 43.00 | 19.76 | 24.7% | 11.3% | 4.1% | 6.2% | +5.9% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹420 Cr | 12.30 | 8.20 | — | 30.0% | 16.7% | 21.5% | -15.2% |
As of Q4 FY26
Financials
Biofil Chemicals & Pharmaceuticals Limited
NSE: BIOFILCHEM · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Biofil Chemicals & Pharmaceuticals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Biofil Chemicals and Pharmaceuticals Ltd is an Indian company engaged in the manufacturing and trading of pharmaceutical and chemical products. The company operates through two primary divisions and provides job work facilities for pharmaceutical drug manufacturing.
Business Model
The company generates revenue through the direct sale of pharmaceutical and chemical products alongside providing contract manufacturing services for third-party drug production.
Growth Outlook
Growth is expected to be driven by the expansion of its pharmaceutical and chemical manufacturing capabilities and the utilisation of its job work facilities.
Key Risks
- Regulatory Compliance. The pharmaceutical sector is subject to stringent government regulations and quality standards that can impact operational continuity.
- Market Competition. Intense competition within the Indian pharmaceutical and chemical landscape may exert pressure on profit margins.
- Raw Material Price Volatility. Fluctuations in the cost of chemical inputs can significantly affect the production costs and overall profitability of the company.
Start your research today
Unlock AI insights, financials, peers and live data on Biofil Chemicals & Pharmaceuticals Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹28 Cr
TTM · standalone
NET PROFIT
₹3 Cr
TTM · standalone
EPS
₹1.71
TTM · standalone
RETURN ON EQUITY
14.3%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
17.4%
TTM · standalone
P/E
17.1x
Q4 FY26 · standalone
EV/EBITDA
14.8x
Q4 FY26 · standalone
EBITDA MARGIN
13.2%
TTM · standalone
NET PROFIT MARGIN
2.8%
Q4 FY26 · standalone
DEBT TO EQUITY
0.1x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26